North America is the largest regional market for PD-L1 inhibitors because of advanced oncology infrastructure, strong clinical-trial activity, reimbursement pathways, and broad access to cancer biomarker testing.
Europe is also a major market, supported by national cancer plans, academic research networks, and growing use of immunotherapy across public healthcare systems. Germany, France, the...
Bangla